Currently, rt-PA (Recombinant tissue plasminogen activator) is one of the most commonly used thrombolytic drugs, which exerts a good therapeutic effect within 3–4.5 h of onset in patients with ischemic stroke, but may cause ischemia/reperfusion (I/R) injury once the appropriate therapeutic time window is exceeded [3]. This evidence concerns the gene PLAT and ischemic stroke.